Patents by Inventor Caroline Gilbert

Caroline Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1)
    Patent number: 9731001
    Abstract: The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: August 15, 2017
    Assignee: Universite Laval
    Inventors: Caroline Gilbert, Michel J. Tremblay, Sheng-Xiang Lin, Arezki Azzi, Alexandra Lambert
  • Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (DCIR) activity and signaling events
    Patent number: 9320773
    Abstract: The invention is concerned with methods, compounds and pharmaceutical compositions for interfering dendritic cell immunoreceptor (DCIR) activity and signalling events. Described herein are compounds useful in targeting one or more of intracellular modulators and the uses thereof for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus (HIV) binding, entry and/or replication in human cells. Exemplary compounds include peptides and antisense molecules.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: April 26, 2016
    Assignee: Université Laval
    Inventors: Caroline Gilbert, Alexandra Lambert, Michel J. Tremblay
  • THREE-DIMENSIONAL CAVITIES OF DENDRITIC CELL IMMUNORECEPTOR (DCIR), COMPOUNDS BINDING THERETO AND THERAPEUTIC APPLICATIONS RELATED TO INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1)
    Publication number: 20150157705
    Abstract: The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.
    Type: Application
    Filed: December 20, 2012
    Publication date: June 11, 2015
    Inventors: Caroline Gilbert, Michel J. Tremblay, Sheng-Xiang Lin, Arezki Azzi, Alexandra Lambert
  • Method for inhibiting dendritic cell immunoreceptor (DCIR)-mediated human immunodeficiency virus infection comprising administering anti-DCIR antibodies
    Patent number: 8609100
    Abstract: A cell surface molecule designated DCIR (for dendritic cells ImmunoReceptor), a member of a recently described family of DC-expressing C-type lectin receptors, has been shown to participate to the capture of human immunodeficiency virus (HIV) and promote infection in trans and in cis of autologous CD4(+) T cells from human immature monocyte-derived DC. The contribution of DCIR to these processes was revealed using DCIR-specific siRNAs and a polyclonal antibody specific for the carbohydrate recognition domain of DCIR. Therapeutic agents for HIV infection are therefore provided herein. These therapeutic agents are useful for impairing the interaction between DCIR and HIV and as such may be useful for treatment or prevention of HIV infection. Also provided are assays for identifying additional therapeutics agents for treatment or prevention HIV infection.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: December 17, 2013
    Assignee: Universite Laval
    Inventors: Alexandra Lambert, Caroline Gilbert, Michel J. Tremblay
  • COMPOUNDS AND THERAPEUTIC APPLICATIONS RELATED TO INHIBITION OF DENDRITIC CELL IMMUNORECEPTOR (DCIR) ACTIVITY AND SIGNALING EVENTS
    Publication number: 20130267461
    Abstract: The invention is concerned with methods, compounds and pharmaceutical compositions for interfering dendritic cell immunoreceptor (DCIR) activity and signalling events. Described herein are compounds useful in targeting one or more of intracellular modulators and the uses thereof for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus (HIV) binding, entry and/or replication in human cells. Exemplary compounds include peptides and antisense molecules.
    Type: Application
    Filed: August 4, 2011
    Publication date: October 10, 2013
    Applicant: Universite Laval
    Inventors: Caroline Gilbert, Alexandra Lambert, Michel J. Tremblay
  • IDENTIFICATION OF THERAPEUTIC AGENTS FOR HIV INFECTION
    Publication number: 20120039894
    Abstract: A cell surface molecule designated DCIR (for dendritic cells ImmunoReceptor), a member of a recently described family of DC-expressing C-type lectin receptors, has been shown to participate to the capture of human immunodeficiency virus (HIV) and promote infection in trans and in cis of autologous CD4(+) T cells from human immature monocyte-derived DC. The contribution of DCIR to these processes was revealed using DCIR-specific siRNAs and a polyclonal antibody specific for the carbohydrate recognition domain of DCIR. Therapeutic agents for HIV infection are therefore provided herein. These therapeutic agents are useful for impairing the interaction between DCIR and HIV and as such may be useful for treatment or prevention of HIV infection. Also provided are assays for identifying additional therapeutics agents for treatment or prevention HIV infection.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 16, 2012
    Inventors: Alexandra LAMBERT, Caroline Gilbert, Michel J. Tremblay
  • Identification of therapeutic agents for HIV infection
    Publication number: 20100061991
    Abstract: A cell surface molecule designated DCIR (for dendritic cells ImmunoReceptor), a member of a recently described family of DC-expressing C-type lectin receptors, has been shown to participate to the capture of human immunodeficiency virus (HIV) and promote infection in trans and in cis of autologous CD4(+) T cells from human immature monocyte-derived DC. The contribution of DCIR to these processes was revealed using DCIR-specific siRNAs and a polyclonal antibody specific for the carbohydrate recognition domain of DCIR. Therapeutic agents for HIV infection are therefore provided herein. These therapeutic agents are useful for impairing the interaction between DCIR and HIV and as such may be useful for treatment or prevention of HIV infection. Also provided are assays for identifying additional therapeutics agents for treatment or prevention HIV infection.
    Type: Application
    Filed: June 18, 2009
    Publication date: March 11, 2010
    Inventors: Alexandra Lambert, Caroline Gilbert, Michel J. Tremblay